HETLIOZ LQ Drug Patent Profile

Which patents cover Hetlioz Lq, and when can generic versions of Hetlioz Lq launch?

Hetlioz Lq is a drug marketed by Vanda Pharms Inc and is included in one NDA. There are twenty-seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and eleven patent family members in twenty-four countries.

The generic ingredient in HETLIOZ LQ is tasimelteon. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the tasimelteon profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hetlioz Lq

A generic version of HETLIOZ LQ was approved as tasimelteon by TEVA PHARMS USA INC on December 12^th, 2022.

Summary for HETLIOZ LQ

International Patents:	211
US Patents:	27
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for HETLIOZ LQ

Paragraph IV (Patent) Challenges for HETLIOZ LQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
HETLIOZ LQ	Oral Suspension	tasimelteon	4 mg/mL	214517	1	2024-04-01

US Patents and Regulatory Information for HETLIOZ LQ

HETLIOZ LQ is protected by twenty-seven US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION;ORAL	214517-001	Dec 1, 2020		RX	Yes	Yes
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION;ORAL	214517-001	Dec 1, 2020		RX	Yes	Yes	11,141,400
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION;ORAL	214517-001	Dec 1, 2020		RX	Yes	Yes	11,918,556

International Patents for HETLIOZ LQ

When does loss-of-exclusivity occur for HETLIOZ LQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Chile

China

Colombia

European Patent Office

Israel

Japan

Mexico

New Zealand

South Africa

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering HETLIOZ LQ around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	9711051
Australia	2018201302	TREATMENT OF CIRCADIAN RHYTHM DISORDERS
Chile	2014001993	Uso de melatonina para el tratamiento de trastornos del ritmo circadiano

Investment Scenario and Fundamentals Analysis of HETLIOZ LQ

Last updated: February 20, 2026

What is HETLIOZ LQ?

HETLIOZ LQ (tasimelteon) is a prescription drug marketed by HETLIOZ LQ, primarily used for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind individuals. It is a melatonin receptor agonist. Approved by the FDA in December 2020, HETLIOZ LQ is designed for once-nightly oral administration.

Market Opportunity

Target Population

• Non-24 affects an estimated 50,000 to 70,000 people worldwide, predominantly those with total blindness.
• The US market estimates range from 5,000 to 10,000 patients.

Unmet Medical Need

• No other approved treatments specifically target Non-24.
• Existing management strategies are insufficient and rely on off-label or symptomatic treatments.

Pricing and Reimbursement

• Listed price: approximately $4,300 per month (varies by insurer).
• Reimbursement depends on health plans, with an emphasis on rare disease coverage as a Breakthrough Therapy.

Market Penetration

• Initial uptake limited to specialized centers.
• Physician awareness campaigns are crucial for broader adoption.

Commercial and Regulatory Perspective

Regulatory Status

• Approved by FDA (December 2020).
• FDA designated Tasimelteon as a Breakthrough Therapy in 2014, accelerating development.

Competition

• Currently, no direct FDA-approved competitors.
• Indirect competition from off-label sedatives and sleep aids.
• Potential for future entrants if similar mechanisms are developed.

Patent Landscape

• Patent exclusivity through composition of matter and method-of-use claims extending until at least 2030.
• Patent challenges are unlikely to influence current valuation but should be monitored.

Financial Performance and Investment Considerations

Revenue Trajectory

• HETLIOZ LQ is early in its commercialization phase.
• Limited historical sales; expect gradual growth based on awareness campaigns.

Key Drivers

• Expansion of approved indications.
• Increased patient diagnosis.
• Expansion into healthcare systems and international markets.

Risks

• Slow adoption due to rarity.
• Competitive developments.
• Reimbursement hurdles.

Fundamental Valuations

Valuation Metrics

• No public sales data; projections are based on market size, pricing, and adoption rates.
• Estimated peak sales: $200 million to $300 million globally.
• Discounted cash flow models suggest early-stage valuation hinges on market growth assumptions.

Investment Thesis

• Potential high-margin product with a niche but unmet market.
• Long-term growth depends on expanding indications and geographic penetration.
• High regulatory risk is mitigated by existing FDA approval.

Strategic Outlook

• Prioritize awareness campaigns among specialists.
• Seek partnerships with healthcare providers for increased patient access.
• Monitor regulatory updates for potential indication expansions or new formulations.

Key Takeaways

• HETLIOZ LQ presents a niche opportunity with limited competition.
• Important to track market penetration and reimbursement landscape.
• Early sales data and clinician adoption rates are critical indicators.
• Patent exclusivity provides a clear pathway for revenue continuity until at least 2030.
• Investment risk remains high, tied to niche market dynamics and regulatory factors.

FAQs

Q1: What is the primary clinical benefit of HETLIOZ LQ?
It improves sleep-wake cycles in totally blind individuals with Non-24, a condition lacking effective approved treatments.

Q2: How large is the potential patient market?
Approximately 5,000 to 10,000 patients in the US, with broader global estimates reaching 70,000.

Q3: What are the main risks for investors?
Limited market size, slow adoption, regulatory challenges for new indications, and reimbursement hurdles.

Q4: How does patent exclusivity affect investment?
Patents extend until at least 2030, providing a period of market exclusivity that supports revenue forecasts.

Q5: Are there competitors to HETLIOZ LQ?
No direct FDA-approved competitors; some off-label sleep aids are used but do not address the specific condition.

---

References

1. Food and Drug Administration. (2020). FDA approves first treatment for non-24-hour sleep-wake disorder.
2. MarketWatch. (2021). U.S. prescription drug pricing.
3. ClinicalTrials.gov. (2020). Tasimelteon studies.
4. HealthEconomics.com. (2022). Rare disease treatment market analysis.
5. PatentScope. (2023). Patent filings related to tasimelteon.